Stem cell and drug discovery scientists around the world are using REPROCELL’s services and products in their preclinical and clinical research.

About REPROCELL

Make an inquiry

REPROCELL Corporate News (4)

Why eTheRNA's mRNA vaccine may offer a long-term solution to COVID

Phase II clinical trial of regenerative medicine product Stemchymal® - Recruitment of first patient

Prof Stefan Przyborski to give Keynote Address at this year’s SMi 3D Cell Culture Conference

Patients with IBD absorb drugs differently from healthy individuals

REPROCELL can now predict oral bioavailability in fresh IBD tissue

Early understanding of pharmacology and genomics can improve precision medicine strategies

Lantern Pharma Selects REPROCELL Inc., for Drug Screening and Biomarker Discovery Services

Appointment of New Distributor in Thailand

REPROCELL Receives MSCRF Grant to Accelerate Stem Cell Drug Discovery Capability for Enabling Neuronal Disease Research and Drug Development

PRESS RELEASE: REPROCELL and NeuCyte enter distribution agreement in North America and Europe

PRESS RELEASE: Axion BioSystems make REPROCELL a product distributor

PRESS RELEASE: ABLE Biott Bioreactors now available in Europe

REPROCELL Launches cGMP suite in Kawasaki to Accelerate Development of iPSC-derived Glial Progenitors for treatment of CNS disorders

REPROCELL and Hanugen to custom manufacture clinical grade oligos for gene therapy

REPROCELL USA Inc. Achieves Quality Management ISO9001:2015 Certification

How the Medical Discovery Catapult is Improving Precision Medicine

UK Government’s science and innovation audit highlights REPROCELL’s work in precision medicine

REPROCELL join Medicines Discovery Catapult’s Virtual R&D network to accelerate drug development

REPROCELL Inc. forms joint venture with Fox Chase Cancer Center to begin operations on biosample repositories

Appointment of New Distributor in China

Subscribe to receive updates